Multicenter registry results suggest a 1% incidence of contrast-induced nephropathy among high-risk

Benephit Renal Infusion Therapy registry shows positive results

Data from a multicenter registry of targeted renal therapy (TRT) in patients at high risk for acute kidney injury—a common complication of hospitalized patients and one that is associated with increased short and long-term mortality—was presented Sunday at the American Society of Nephrology’s Renal Week 2007 by James A. Tumlin, M.D., nephrologist, Clinical Research Division, Southeast Renal Associates, Charlotte, N.C.TRT is the delivery of physician-specified therapeutic agents directly to the kidneys via the renal arteries through the innovative Benephit Infusion Systems from FlowMedica, Inc. TRT may offer significant benefit in direct infusion of therapeutic levels of medications without the side effects that can be encountered with conventional IV delivery.Dr. Tumlin’s presentation, “Intra-Renal Infusion with Fenoldopam Mesylate Reduces Acute Kidney Injury Following Cardiothoracic Surgery or Exposure to Iodinated Contrast Agents: Results from the Be-RITe Registry,” included the analysis of 501 patients enrolled in the Be-RITe Registry. The presentation of the registry results was the first time the data has been presented at the ASN meetings.

read the full article: http://www.nephronline.com/nephnews/index.php?option=com_content&task=view&id=1719&Itemid=1